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Abstract
Correction to Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S and
Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral
antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of
General Psychiatry 2008, 7:16. This correction reports changes in the values listed for Ziprasidone
and Aripiprazole in Table Ten.
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Correction
Following the publication of our article [1], it has come to
our attention that there was an error with the values listed
for Ziprasidone and Aripiprazole in Table Ten. Table Ten
should therefore appear as shown in this correction (Table
1).
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Table 1: Mean annual number of stable days and cost per patient by pharmaceutical treatment.
Paliperidone ER Olanzapine Risperidone Quetiapine Ziprasidone Aripiprazole
Base case:
Cost (€) 7.030 7.034 7.082 8.321 7.807 7.713
Effectiveness 272.5 272.2 265.5 260.7 258.6 260.5
Incremental cost and effectiveness compared with paliperidone ER:
Cost (€) - 4 52 1.291 777 683
Effectiveness - -0.3 -7.0 -11.8 -13.9 -12.0